These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1029 related articles for article (PubMed ID: 28237835)

  • 61. Adeno-Associated Viral Vectors for Homology-Directed Generation of CAR-T Cells.
    Moço PD; Aharony N; Kamen A
    Biotechnol J; 2020 Jan; 15(1):e1900286. PubMed ID: 31642193
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
    Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
    J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.
    Rozenbaum M; Meir A; Aharony Y; Itzhaki O; Schachter J; Bank I; Jacoby E; Besser MJ
    Front Immunol; 2020; 11():1347. PubMed ID: 32714329
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
    Cohen AD
    Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Challenges and opportunities of allogeneic donor-derived CAR T cells.
    Yang Y; Jacoby E; Fry TJ
    Curr Opin Hematol; 2015 Nov; 22(6):509-515. PubMed ID: 26390167
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice.
    Hu X; Manner K; DeJesus R; White K; Gattis C; Ngo P; Bandoro C; Tham E; Chu EY; Young C; Wells F; Basco R; Friera A; Kangeyan D; Beauchesne P; Dowdle WE; Deuse T; Fry TJ; Foster AE; Schrepfer S
    Nat Commun; 2023 Apr; 14(1):2020. PubMed ID: 37037829
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.
    Hudecek M; Gogishvili T; Monjezi R; Wegner J; Shankar R; Kruesemann C; Miskey C; Ivics Z; Schmeer M; Schleef M
    Recent Results Cancer Res; 2016; 209():37-50. PubMed ID: 28101686
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 70. CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products.
    Kath J; Du W; Martini S; Elsallab M; Franke C; Hartmann L; Drosdek V; Glaser V; Stein M; Schmueck-Henneresse M; Reinke P; Volk HD; Abou-El-Enein M; Wagner DL
    Blood Adv; 2023 Aug; 7(15):4124-4134. PubMed ID: 37196643
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
    Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
    [TBL] [Abstract][Full Text] [Related]  

  • 72. In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC.
    Ueda T; Kaneko S
    Methods Mol Biol; 2019; 2048():85-91. PubMed ID: 31396933
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells.
    Kamiya T; Wong D; Png YT; Campana D
    Blood Adv; 2018 Mar; 2(5):517-528. PubMed ID: 29507075
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
    Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.
    Lock D; Mockel-Tenbrinck N; Drechsel K; Barth C; Mauer D; Schaser T; Kolbe C; Al Rawashdeh W; Brauner J; Hardt O; Pflug N; Holtick U; Borchmann P; Assenmacher M; Kaiser A
    Hum Gene Ther; 2017 Oct; 28(10):914-925. PubMed ID: 28847167
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street.
    Barrett DM; Grupp SA; June CH
    J Immunol; 2015 Aug; 195(3):755-61. PubMed ID: 26188068
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.
    Khurana A; Lin Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):171-187. PubMed ID: 35212892
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies.
    Freiwan A; Zoine JT; Crawford JC; Vaidya A; Schattgen SA; Myers JA; Patil SL; Khanlari M; Inaba H; Klco JM; Mullighan CG; Krenciute G; Chockley PJ; Naik S; Langfitt DM; Mamonkin M; Obeng EA; Thomas PG; Gottschalk S; Velasquez MP
    Blood; 2022 Dec; 140(25):2684-2696. PubMed ID: 35914226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.